Clinical data and pooled analyses reported that combining radiotherapy with immunotherapy improves outcomes in several difficult cancers. A phase Ib trial showed toripalimab added to concurrent chemoradiotherapy produced promising safety and efficacy signals in locally advanced cervical cancer, while a pooled analysis found brain radiotherapy plus atezolizumab with platinum chemotherapy extended survival in NSCLC patients with brain metastases. Investigators highlighted sequencing and timing as key variables when integrating RT and checkpoint inhibitors, and both studies emphasized the need for prospective validation to define patient selection and toxicity management. Clinical takeaways: Radiation can act as an in situ vaccine and may potentiate checkpoint blockade, but carefully designed trials are required to optimize radiosensitization while managing immune‑related adverse events.